Human NT-proCNP ELISA

Catalog number: BI-20812
Brand: Biomedica
Packing: 96 tests
Price: € 783.00
Expected delivery time: 7 days
Quantity:

Product specifications for - Human NT-proCNP ELISA

Overview: 
Product group: Assays
Category: ELISA / EIA
Application note: ELISA
Species: Human
Reactivity note: human
Properties: 
Molecular weight: 4.985 kDa
Assay Sensitivity: 0.7 pmol/l (= 3.49 pg/ml)
Assay Specificity: NT-proCNP (N-Terminal C-type Natriuretic Peptide)
Assay Precision: intra-assay: 6%, inter-assay: 7%
Assay Sample Type: Serum, EDTA plasma, heparin plasma, citrate plasma
Assay Time: 20 min / 2 h / 30 min
Assay Detection Range: 4-128 pmol/l
Datasheet: Datasheet
  Research Use Only
UNSPSC: 41116133
Scientific information: 
Scientific info: Product Characteristics: The Biomedica NT-proCNP Sandwich ELISA kit is a test that is intended for the quantitative measurement of N-terminal C-type natriuretic peptide levels in human serum and plasma samples. The Biomedica NT-proCNP ELISA is CE certified and approved for in-vitro diagnostic use in the EU.Target information: C-type natriuretic peptide (CNP) is a paracrine growth factor widely expressed in tissues, including the vascular endothelium, where it is considered to provide vasoprotective functions. In endothelial cells and macrophages it is secreted in response to several stimuli, including inflammatory mediators. CNP is rapidly degraded in tissues and negligible quantities enter the circulation. However, the N-terminal portion of the pro-hormone is not degraded at source and circulates in significantly higher concentrations than CNP. Therefore NT-proCNP is a valuable biomarker to determine CNP synthesis in tissues. CNP plays a critical role in linear growth. It is produced in the growth plate and signals through a paracrine mechanism. Recent studies have shown that the plasma concentrations of NT-proCNP correlate with linear growth velocity in all phases of skeletal growth and increase during rhGH therapy. Furthermore, serum NT-proCNP levels increased after initiation of GH treatment in patients with achondroplasia/ hypochondroplasia. Women with pregnancy complications, such as diminished fetal growth and pre-eclampsia show significantly increased NT-proCNP levels early in gestation. NT-proCNP concentration at hospital admission has sufficient sensitivity and specificity to differentiate naturally occurring sepsis from non-septic systemic inflammatory response syndrome (SIRS). Recently, Prickett and colleages demonstrated in a cohort of over 2000 individuals, that in contrast to the close association of NT-proBNP with cardiac function, and predictive value for outcome after myocardial infarction, plasma NT-proCNP is highly correlated with renal function and is an independent predictor of mortality and cardiac readmission in individuals with unstable angina.
Gene ID: 4880
Swiss prot ID: P23582
Safety information: 
MSDS: MSDS
Additional information: 
Synonyms: BI-20812; Biomedica Gruppe
Ehler J et al., “Diagnostic value of NT-proCNP compared to NSE and S100B in cerebrospinal fluid and plasma of patients with sepsis-associated encephalopathy.” Neurosci Lett. (2019); Jan 23;692:167-173. Read more
Espiner E et al., “Plasma C-Type Natriuretic Peptide: Emerging Applications in Disorders of Skeletal Growth.” Horm Res Paediatr. 2018;90(6):345-357. Read more
Kubota T et al., “Serum NT-proCNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia.” Clin Endocrinol (Oxf). (2016); Jun;84(6):845-50. Read more
All Citations Read more